Rhone Ma Holdings Bhd

Rhone Ma Holdings Bhd maintains a conservative capital structure with a debt-to-equity ratio of 0.18, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 4.75, suggesting strong short-term liquidity. However, the company's net cash position is negative after subtracting total debt, which could signal potential liquidity constraints in the near term. In terms of profitability, the company's return on equity (ROE) is 1.96%, and its return on assets (ROA) is 1.42%. These figures are below the industry median for ROE and ROA in the pharmaceutical sector, indicating that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The company's revenue is primarily concentrated in Malaysia and Southeast Asia, with no disclosed breakdown of segment or geographic revenue. This lack of diversification could expose the company to regional economic and regulatory risks, particularly in a sector that is highly sensitive to healthcare policy changes. Looking ahead, the company's growth trajectory is expected to remain modest, with no significant revenue growth projected in the current or next fiscal year. Historical revenue trends show a stable but non-explosive growth pattern, which is consistent with the company's current market position and industry dynamics. The company's risk profile is moderate, with a low dilution risk and a medium liquidity risk. The risk assessment highlights a key flag: the company's net cash is negative after subtracting total debt, which could impact its ability to fund operations or invest in growth opportunities without external financing. Recent filings and transcripts do not indicate any major strategic shifts or significant events that would alter the company's current trajectory. The company appears to be maintaining a steady course, with no major new product launches or market expansions disclosed in the latest available documents.